SMMT logo

SUMMIT THERAPEUTICS INC

SMMTNASDAQ
🏆 #773 by market capUS Equity
$222.49▲ $19.31 (+8.68%)
Simulated price
🔔
Track SMMT
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 8.7%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$12.45B
Mid Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
84
Good
No chart data available for SMMT.

Trading Snapshot

Day Range
$219.11 – $225.32
52-Week Range
$12.07 – $29.23
Volume
$1.75B
Avg Volume
$1.50B
Shares Outstanding
797.7M
Next Earnings
Dec 8, 2026

Fundamentals Snapshot

Annual Revenue
$1.62B
Last Q Revenue
$391M
P/E Ratio
-13.9
P/S Ratio
0.0x
EPS (TTM)
$-1.10
Dividend Yield
0.00%

Why Investors Own SMMT

  • ✓High-growth profile — revenue up +41.6% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 67% gross margin and 5% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

SMMT logo

SUMMIT THERAPEUTICS INC

SMMT
Financial Trends
Revenue (TTM)The total money the company brought in from sales, before subtracting any costs.
$1.62B▲ +36.0% YoY
Gross Margin (TTM)Of every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
67.4%▲ +1.8% YoY
Operating Income (TTM)Profit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$243M▲ +36.0% YoY
Free Cash Flow (TTM)Cash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$87M▲ +36.0% YoY
StockOtter · stockotter.space

About SUMMIT THERAPEUTICS INC

Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
84/100

Analyst Price Target

ⓘ
Average Target
$270.21
▲ +21.4% Upside
High Target$315.08
Low Target$212.08
Based on 21 analysts

Latest News & Updates

🚀
CNBC·2h ago

SUMMIT THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift SMMT price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

SUMMIT THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.